Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Anthraquinone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 7/20 | 0.78 |
| ▸ | PTGS1 known ✓ | P23219 | 5/20 | 0.78 |
| ▸ | CXCR1 | P25024 | 4/20 | 0.78 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.78 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.78 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.78 |
| ▸ | ALB | P02768 | 1/20 | 0.78 |
| ▸ | ESR1 | P03372 | 1/20 | 0.78 |
| ▸ | RARB | P10826 | 1/20 | 0.78 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.78 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.78 |
| ▸ | HTR2A | P28223 | 1/20 | 0.78 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.78 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.78 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.78 |
| ▸ | BLM | P54132 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibuprofen SCHEMBL2648936 | 0.96 | PTGS2 (0.71) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| Ibuprofen SCHEMBL9310520 | 0.96 | PTGS2 (0.71) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| Dexibuprofen SCHEMBL30091137 | 0.88 | PTGS1 (1.00) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| Ibuprofen SCHEMBL239446 | 0.88 | PTGS1 (1.00) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| (R)-Ibuprophen SCHEMBL29057 | 0.88 | PTGS1 (1.00) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| Ibuprofen SCHEMBL3001 | 0.88 | PTGS1 (1.00) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| Ibuprofen SCHEMBL19439560 | 0.88 | PTGS1 (1.00) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| Ibuprofen SCHEMBL19439559 | 0.88 | PTGS1 (1.00) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| Ibuprofen SCHEMBL8754799 | 0.88 | PTGS1 (1.00) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| Dexibuprofen SCHEMBL43531 | 0.88 | PTGS1 (1.00) | PTGS2PTGS1CXCR1CXCR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104225612-A | Preparation and applications of oral absorption enhancer built based on natural P-glycoprotein inhibitor | UNIV CHINA PHARMA | 2014-12-24 | — | — | CN | claimed |
| CN-117883500-A | Composition containing anti-inflammatory active ingredients and preparation method and application thereof | 广州腾麟生物科技有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-114107240-B | Tartary buckwheat-derived large Huang Sutang transferase, and encoding gene and application thereof | 中国农业科学院作物科学研究所 | 2024-02-02 | — | — | CN | disclosed |
| EP-4187242-A1 | QUALITY CONTROL METHOD OF DAMPNESS-RESOLVING AND TOXIN-VANQUISHING COMPOSITION | Guangdong Yifang Pharmaceutical Co., Ltd (CN) | 2023-05-31 | — | — | EP | disclosed |
| CN-115192590-A | Inhibition of glycyrrhizin A3 on novel coronavirus spike protein and pharmaceutical application thereof | 北京大学 | 2022-10-18 | — | — | CN | disclosed |
| CN-115040586-A | Traditional Chinese medicine composition for preventing and treating alopecia | 湖北诗云生物科技有限公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-114107240-A | Tartary buckwheat-derived emodin glycosyltransferase and coding gene and application thereof | 中国农业科学院作物科学研究所 | 2022-03-01 | — | — | CN | disclosed |
| CN-113662921-A | Obeticholic acid pharmaceutical composition, and preparation method and application thereof | 北京四环制药有限公司 | 2021-11-19 | — | — | CN | disclosed |
| CN-112180000-B | Method for detecting dampness-resolving and toxin-vanquishing composition | 广东一方制药有限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-10894054-B2 | FXR agonist compositions for combination therapy | INTERCEPT PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| EP-1796656-A2 | COMPOSITION FOR INHIBITING OR PREVENTING THE FORMATION OF A BIOFILM | Oystershell NV (BE) | 2007-06-20 | — | — | EP | disclosed |
| US-20060263864-A1 | Methods for improving secondary metabolite production of fungi | MICROBIA PRECISION ENGINEERING, INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006029893-A2 | COMPOSITION FOR INHIBITING OR PREVENTING THE FORMATION OF A BIOFILM | OYSTERSHELL NV (BE) | 2006-03-23 | — | — | WO | disclosed |
| EP-1370271-B1 | A PROCESS FOR THE MANUFACTURE OF A HERBAL COMPOSITION COMPRISING A MATRINE | GLOBAL CANCER STRATEGIES LTD (CA) | 2005-10-05 | — | — | EP | disclosed |
| US-20040170704-A1 | Process for the manufacture of a herbal composition | GLOBAL CANCER STRATEGIES LTD. (CA) | 2004-09-02 | — | — | US | disclosed |
| WO-2004058185-A2 | ANTIANGIOGENESIS BY INHIBITING PROTEIN KINASE CK2 ACTIVITY | CEDARS-SINAI MEDICAL CENTER (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040121968-A1 | Antiangiogenesis by inhibiting protein kinase CK2 activity | CEDARS-SINAI MEDICAL CENTER | 2004-06-24 | — | — | US | disclosed |
| EP-1370271-A2 | A PROCESS FOR THE MANUFACTURE OF A HERBAL COMPOSITION COMPRISING A MATRINE | Global Cancer Strategies Ltd. (CA) | 2003-12-17 | — | — | EP | disclosed |
| US-20030099725-A1 | Herbal compositions useful as chemopreventive and therapeutic agents and methods of manufacturing same | GLOBAL CANCER STRATEGIES LTD. | 2003-05-29 | — | — | US | disclosed |
| WO-2002067955-A2 | A PROCESS FOR THE MANUFACTURE OF A HERBAL COMPOSITION COMPRISING A MATRINE | GLOBAL CANCER STRATEGIES LTD. (CA) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894054-B2 | FXR agonist compositions for combination therapy | GPR119, FXR1, NR1H4 | PTGS2 2730/4885PTGS1 2171/4885CXCR1 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.